BR112014025740A2 - Vaccines and Methods to Treat Lyme Disease in Dogs - Google Patents
Vaccines and Methods to Treat Lyme Disease in DogsInfo
- Publication number
- BR112014025740A2 BR112014025740A2 BR112014025740A BR112014025740A BR112014025740A2 BR 112014025740 A2 BR112014025740 A2 BR 112014025740A2 BR 112014025740 A BR112014025740 A BR 112014025740A BR 112014025740 A BR112014025740 A BR 112014025740A BR 112014025740 A2 BR112014025740 A2 BR 112014025740A2
- Authority
- BR
- Brazil
- Prior art keywords
- dogs
- vaccines
- lyme disease
- methods
- immunogenic composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo vacinas e métodos para tratar a doença de lyme em cães a presente invenção fornece uma composição imunogênica que compreende um fragmento antigênico da proteína ospa de borrelia burgdorferi e uma proteína quimérica contendo fragmentos antigênicos de diferentes filotipos da proteína ospc de borrelia burgdorferi. as vacinas que incorporam a composição imunogênica da invenção, bem como os métodos para prevenir a doença de lyme em cães e / ou proteger os cães de contrair a doença de lyme ao usar as vacinas, são também fornecidos.Abstract Vaccines and Methods for Treating Lyme Disease in Dogs The present invention provides an immunogenic composition comprising an antigenic fragment of the ospa protein from Borrelia burgdorferi and a chimeric protein containing antigenic fragments from different phylotypes of the ospc protein from Borrelia burgdorferi. vaccines incorporating the immunogenic composition of the invention, as well as methods of preventing lyme disease in dogs and/or protecting dogs from contracting lyme disease when using the vaccines, are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261635031P | 2012-04-18 | 2012-04-18 | |
PCT/US2013/037063 WO2013158818A2 (en) | 2012-04-18 | 2013-04-18 | Vaccines and methods to treat lyme disease in dogs |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014025740A2 true BR112014025740A2 (en) | 2017-07-04 |
Family
ID=48193279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014025740A BR112014025740A2 (en) | 2012-04-18 | 2013-04-18 | Vaccines and Methods to Treat Lyme Disease in Dogs |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2838555A2 (en) |
JP (1) | JP2015514776A (en) |
CN (1) | CN104379164A (en) |
AR (1) | AR090726A1 (en) |
AU (1) | AU2013249229A1 (en) |
BR (1) | BR112014025740A2 (en) |
CA (1) | CA2870179C (en) |
EA (1) | EA201491668A1 (en) |
UY (1) | UY34745A (en) |
WO (1) | WO2013158818A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3204404A4 (en) | 2014-10-08 | 2018-06-06 | Virginia Commonwealth University | Stage specific diagnostic antigens, assay and vaccine for lyme disease |
US11883476B2 (en) | 2017-12-04 | 2024-01-30 | Intervet Inc. | Canine lyme disease vaccine |
CN110483624B (en) * | 2019-08-22 | 2021-02-09 | 中国疾病预防控制中心传染病预防控制所 | Borrelia garinii OspA protein C-terminal peptide segment and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567042A (en) | 1983-06-15 | 1986-01-28 | American Home Products Corporation | Inactivated canine coronavirus vaccine |
US4567043A (en) | 1983-06-15 | 1986-01-28 | American Home Products Corporation (Del.) | Canine corona virus vaccine |
US6872550B1 (en) | 1991-07-11 | 2005-03-29 | Baxter Vaccine Ag | Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
ATE181572T1 (en) * | 1991-08-15 | 1999-07-15 | Smithkline Beecham Biolog | OSPA PROTEINS OF BORRELIA BURGDORFERI SUBGROUPS, GENES CODING FOR THEM AND VACCINES |
PT1100922E (en) | 1998-07-31 | 2008-05-30 | Gundersen Lutheran Medical Fou | Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine |
WO2009135118A2 (en) * | 2008-05-02 | 2009-11-05 | Virginia Commonwealth University | Lyme disease vaccine |
WO2010132758A2 (en) * | 2009-05-14 | 2010-11-18 | Gomes-Solecki Maria J | Ospc-based diagnostic test for lyme disease |
US8808705B2 (en) * | 2010-10-20 | 2014-08-19 | Virginia Commonwealth University | Polyvalent chimeric OspC vaccinogen and diagnostic antigen |
-
2013
- 2013-04-16 UY UY0001034745A patent/UY34745A/en not_active Application Discontinuation
- 2013-04-17 AR ARP130101267A patent/AR090726A1/en unknown
- 2013-04-18 BR BR112014025740A patent/BR112014025740A2/en not_active IP Right Cessation
- 2013-04-18 WO PCT/US2013/037063 patent/WO2013158818A2/en active Application Filing
- 2013-04-18 JP JP2015507162A patent/JP2015514776A/en active Pending
- 2013-04-18 EP EP13719257.1A patent/EP2838555A2/en not_active Withdrawn
- 2013-04-18 CA CA2870179A patent/CA2870179C/en active Active
- 2013-04-18 AU AU2013249229A patent/AU2013249229A1/en not_active Abandoned
- 2013-04-18 EA EA201491668A patent/EA201491668A1/en unknown
- 2013-04-18 CN CN201380030342.1A patent/CN104379164A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2838555A2 (en) | 2015-02-25 |
EA201491668A1 (en) | 2015-08-31 |
JP2015514776A (en) | 2015-05-21 |
AR090726A1 (en) | 2014-12-03 |
CN104379164A (en) | 2015-02-25 |
WO2013158818A2 (en) | 2013-10-24 |
AU2013249229A1 (en) | 2014-10-23 |
CA2870179A1 (en) | 2013-10-24 |
WO2013158818A3 (en) | 2014-04-17 |
CA2870179C (en) | 2018-09-04 |
UY34745A (en) | 2013-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017014258A2 (en) | anti-cd47 antibodies and uses thereof | |
AR090465A1 (en) | SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PROFARMACO | |
BR112014028476A2 (en) | immunogenic fragment of a polypeptide, isolated polynucleotide, immunogenic pharmaceutical composition, methods for treating an infection, for generating an immune response in a subject, and for immunizing a subject | |
BR112014008294A2 (en) | anti c-met antibody and uses of it | |
BR112015012933A2 (en) | bcma antigen binding proteins | |
ECSP15025845A (en) | ANTI-CEACAM5 ANTIBODIES AND USES OF THEM | |
BR112015022191A8 (en) | heteroaryl compounds and uses thereof | |
BR112017002761A2 (en) | anti-methanogenic compositions and uses thereof | |
BR112016013493A2 (en) | nucleic acid molecule, composition, vaccine, and methods for preventing a disease in an individual in need thereof and for treating a disease in an individual in need thereof | |
CL2014001994A1 (en) | Synthetic apeline mimetic polypeptide for treatment and heart failure; pharmaceutical composition comprising said polypeptide. | |
BR112014023937A2 (en) | pharmaceutical composition, pharmaceutical combination and treatment method | |
CL2015003343A1 (en) | Pharmaceutical composition comprising a modified therapeutic agent based on hemoglobin, for the treatment to treat cancer, and diagnostic images. | |
BR112019012796A2 (en) | antineuropillin antigen binding proteins and methods of use thereof | |
CY1120772T1 (en) | Mutated OspA FRAGMENTS AND RELATED METHODS AND USES | |
BR112014021104A2 (en) | methods and compositions for the treatment of huntington's disease | |
BR112014021531A2 (en) | compound, pharmaceutical composition and uses thereof | |
BR112012027315A8 (en) | chimeric polypeptide, composition, chimeric nucleic acid molecule, vector, host cell, polypeptide production process, combined vaccine, and methods for inducing an immune response and for preventing or treating an infection or disease | |
BR112012005860A2 (en) | peptides isolated from spider venom, and uses thereof | |
BR112017004197A2 (en) | Dengue virus disease vaccine compositions | |
BR112015032763A2 (en) | soluble cd33 to treat myelodysplastic syndromes (mds) | |
BR112014031512A2 (en) | cosmetic composition and method for cosmetic treatment. | |
AR093620A1 (en) | BMP-6 ANTIBODIES | |
MX369195B (en) | Mutant fragments of ospa and methods and uses relating thereto. | |
BR112015008745A2 (en) | method for treating spinal cord injury using hmgb1 fragment | |
BR112016029024A2 (en) | texaphyrin-pt (iv) conjugates and compositions for use in overcoming platinum resistance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |